Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema
NCT05636579Phase 1Recruiting
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of EO2002 in corneal edema, Fuchs endothelial dystrophy (FED) and pseudophakic bullous keratopathy (PBK) (2 arms), sponsored by Asociación para Evitar la Ceguera en México. Primary endpoint: Safety and Tolerability of multiple doses of EO2002 at 32 weeks. Started Nov 2022; status: recruiting.
02
Drugs
EO2002
03
Conditions
corneal edemaFuchs endothelial dystrophy (FED)pseudophakic bullous keratopathy (PBK)
Beyond the preview
Go deeper on NCT05636579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636579.